Coronavirus.

[CroydonDog]

Breadmakers are for lazy people. Bake like a real baker.

Freezers are also for lazy people, I should be salting my meat like they did in the pre refrigeration days.

 

[CrittaMagic69]

Freezers are also for lazy people, I should be salting my meat like they did in the pre refrigeration days.

Doesn't that sting?

 

[Packstar]

I found some online $30 bucks with postage. Not bad for one roll.

View attachment 13739

These motherfuckers need to be found.

1. Confiscate all the toilet paper, paper towels and tissues they have stockpiled

2. Flog the living daylights out of the *****.

3. Smash every toilet bowl in their house

4. Charge the *****

 

[south of heaven]

Is it? I can finally play with you guys

Yep

 

[Packstar]

Fkn love them bro, I have to fight with the kids over them lol

As a kid i loved them more than the grape and strawberry nerds

 

[Mr 95%]

Breadmakers are for lazy people. Bake like a real baker.

Especially if you um..kneed..it!

 

[CroydonDog]

Doesn't that sting?

Freezing my meat? Well,you would have to worry about it sticking.

 

[DinkumDog]

So disappointed in Tom Hanks:

- He survived 4 years castaway on an island
- Spent a year in an airport without being able to leave
- Fought in WWII and rescued Private Ryan
- Fought in Vietnam and rescued Lieutenant Dan
- Fought off Somali pirates and saved his container ship at sea
- Survived Apollo 13 in trying to reach the moon
- Landed an A320 on the Hudson River saving everyone onboard

...Yet contracts COVID-19 on the Gold Coast. Sheesh.

 

[Packstar]

Corona and all the scavengers can go and fuck themselves

Sorted for atleast 8 months of homemade salt-cured, cold smoked delicious meats

 

[MatstaDogg]

If only I had known about TK in 04, took me a most of my years as a supporter to come across this place. I don’t even know how I did lol, but very glad I found my second family life wouldn’t be the same without it. Definitely a privilege to be here.

Yeah I didn't know it existed and only came across it while looking up a bulldogs related article. Lurked for a little bit before joining up in 08.

 

[Heckler]

Shove laxatives down their gobs as well

These motherfuckers need to be found.

1. Confiscate all the toilet paper, paper towels and tissues they have stockpiled

2. Flog the living daylights out of the *****.

3. Smash every toilet bowl in their house

4. Charge the *****

 

[Mr 95%]

The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say


MARK JOHNSON | MILWAUKEE JOURNAL SENTINEL

12:26 pm EDT Mar. 15, 2020

MILWAUKEE, Wis. – In a week when the coronavirus closures and quarantines hit like falling dominoes – the lockdown in Italy, the empty workplaces and college campuses in the U.S., suspended sports seasons, canceled festivals – far less attention fell on the global scientific community's drive to find treatments for the new virus.

But researchers are already suggesting strategies to help patients suffering from the virus, which is marked by fever, coughing and difficulty breathing. One treatment could be just weeks away.

With no vaccine expected anytime soon, treatments are crucial to saving the lives of thousands of the infected, especially high-risk patients – the elderly, those with compromised immune systems and those with chronic illnesses, such as diabetes, heart disease and lung disease.

"I'm very hopeful and very positive. We'll get through this," said Robert Kruse, a doctor in the Department of Pathology at Johns Hopkins Hospital in Baltimore. "I've been shocked this week at the measures that have been taken (to alter daily life). They were probably the correct ones, given that they have worked in other countries."

'Time is of the essence'

Kruse has been pursuing two different treatment strategies, one of which has a long history and could be available within weeks rather than months. The quickest option is likely to be the use of antibodies from recovered COVID-19 patients. As of Saturday, there were almost 72,000 such patients worldwide. The virus has infected about 150,000, killing more than 5,500.

The use of survivor antibodies, serum therapy, dates back to 1891 when it was used successfully to treat a child with diphtheria. Since then, serum from recovered patients has been used "to stem outbreaks of viral diseases such as poliomyelitis, measles, mumps and influenza," according to a paper Friday in The Journal of Clinical Investigation.

"As we are in the midst of a worldwide pandemic, we recommend that institutions consider the emergency use (of serum from recovered patients) and begin preparations as soon as possible. Time is of the essence," wrote the paper's two authors, Arturo Casadevall of Johns Hopkins School of Public Health, and Liise-anne Pirofski of the Albert Einstein College of Medicine in New York.

All of the strategies, including the use of serum from recovered patients, have drawbacks. Transfusion of serum carries potential side effects, including fever, allergic reactions, and a very small risk of infectious disease transmission.

Collecting large amounts of serum from recovered patients could be a sizable task. It could turn out that serum from one recovered patient is only enough to save a single sick one, explained Kruse at Johns Hopkins. "It's a logistical challenge to put it together, but at the very least there are no hurdles (from the U.S. Food and Drug Administration) to producing the therapy."

Kruse advanced another technique in a paper published in late January in the journal F1000 Research.

His method seeks to take advantage of the new coronavirus' ability to latch onto and enter cells.

Scientists often talk about "cell receptors," which are essentially doors that allow a virus to enter the cell.

The "door" the new coronavirus is entering through is known as the ACE-2 protein. Kruse's technique involves detaching the external portion of ACE-2, which would act as a decoy for the virus. The virus would bind to the decoy, leaving it unable to reach the actual door into the cell, and thus, unable to cause infection.

"It won't realize, 'Oh gosh, this isn't a cell,'" Kruse explained in an interview. "The virus can't mutate away from this."

Kruse's decoy therapy would not be available until fall at the earliest. However, a similar version of the strategy is currently being tested in trials in China.

Using a drug for a new purpose

A faster option involves what's called "repurposing" a drug.

This is when a drug that has already been found safe and approved for treatment of one disease also is found useful in treating another. One example is the drug Sildenafil, which is sold as Viagra and used to treat both erectile dysfunction and pulmonary hypertension.

There are three ways in which scientists try to find an existing drug that can treat a new condition.

The rational method involves using drugs that have characteristics and targets that suggest they might be used to treat the new condition.

The computational method involves examining protein structures and using them to predict an existing drug that might work.

The final method takes advantage of the vast drug libraries possessed by companies and academic institutions. High-speed technology allows researchers to screen thousands of drugs very quickly to determine whether they will act against a specific target.

Considerable hope, interest and money have been invested in one drug not previously approved, remdesivir. The drug was previously tested against Ebola, but failed in trials.

Gilead Sciences, a Foster City, California-based biopharmaceutical company, announced that two clinical studies of the drug are beginning this month. Two more clinical trials of the drug are already underway in China.

In the U.S., the clinical trials process is slow and painstaking, taking several years and sometimes much longer.

'The idea is right'

Another approach to the new virus championed by numerous researchers is the use of lab-made proteins called monoclonal antibodies.

These confer what's called "passive immunity" and have been used previously to treat cancer, multiple sclerosis, cardiovascular disease and many other conditions.

"The use of monoclonal antibodies is a new era in infectious disease prevention which overcomes many drawbacks associated with serum therapy ... in terms of specificity, purity, low risk of blood-borne pathogen contamination and safety," wrote the authors of a recent paper in the Asian Pacific Journal of Allergy and Immunology.

The biotechnology company Regeneron, based in Tarrytown, New York, started work searching for a monoclonal antibody "for this particular virus in early/mid-January," said Christos Kyratsous, the company's vice president for infectious diseases and viral vector technologies. "But really we started working on it decades ago when we began building our unique end-to-end drug discovery and development technologies."

Gregory Poland, director of Mayo Clinic's Vaccine Research Group, said the use of monoclonal antibodies "needs to be designed and tested in this specific disease, but I wouldn't see any reason it wouldn't work. The idea is right."

Like other scientists, Poland was less hopeful that a vaccine would be developed anytime soon.

"We won't have a vaccine for this outbreak," he said. "It will be before the next (outbreak)."

Monoclonal antibodies do have pitfalls. They require extensive testing. Also, viruses can mutate and escape from the antibodies. Companies sometimes target two different parts of the virus to make it harder for the virus to mutate and elude the antibodies.

Ajay K. Sethi, associate professor of population health sciences at the University of Wisconsin-Madison, expressed support for the development of monoclonal antibodies.

"In my opinion, trying a strategy like monoclonal antibodies to provide passive immunity is a good idea," Sethi said. He added that given the technique's past successes, "it is hopeful, but not surprising."

Strategies for combating the new coronavirus will likely require reaching patients early before they get too sick. Toward that end, Kruse said he believes the U.S. should pursue the much broader coronavirus testing policy that South Korea adopted.

"Maybe in the next few weeks we will get to the point where we are testing everyone," he said.

12:26 pm EDT Mar. 15, 2020

What do you think @Hacky McAxe and @Lov_Dog and any other Science minded people on the Kennel?

 

[CrittaMagic69]

@south of heaven if it's cross play does that mean I'm playing dudes with a keyboard and mouse on PC? Like I'm blaming them for all my deaths if it is lol

 

[MatstaDogg]

Faaark. All these greedy ***** are gonna be qualified bakers by the time this shit blows over.
Just drink flour and water mixed together and they won't shit for months....saves toilet paper.

Talking of baking, we are getting smashed at work. For the supermarket we supply we have had to triple their order as they keep running out. Pretty much as soon as we but the bread and bread rolls on the shelf they are gone.

 

[Alexander the Great]

43 sold already. *****

These motherfuckers need to be found.

1. Confiscate all the toilet paper, paper towels and tissues they have stockpiled

2. Flog the living daylights out of the *****.

3. Smash every toilet bowl in their house

4. Charge the *****

 

[CroydonDog]

The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say


MARK JOHNSON | MILWAUKEE JOURNAL SENTINEL

12:26 pm EDT Mar. 15, 2020

MILWAUKEE, Wis. – In a week when the coronavirus closures and quarantines hit like falling dominoes – the lockdown in Italy, the empty workplaces and college campuses in the U.S., suspended sports seasons, canceled festivals – far less attention fell on the global scientific community's drive to find treatments for the new virus.

But researchers are already suggesting strategies to help patients suffering from the virus, which is marked by fever, coughing and difficulty breathing. One treatment could be just weeks away.

With no vaccine expected anytime soon, treatments are crucial to saving the lives of thousands of the infected, especially high-risk patients – the elderly, those with compromised immune systems and those with chronic illnesses, such as diabetes, heart disease and lung disease.

"I'm very hopeful and very positive. We'll get through this," said Robert Kruse, a doctor in the Department of Pathology at Johns Hopkins Hospital in Baltimore. "I've been shocked this week at the measures that have been taken (to alter daily life). They were probably the correct ones, given that they have worked in other countries."

'Time is of the essence'

Kruse has been pursuing two different treatment strategies, one of which has a long history and could be available within weeks rather than months. The quickest option is likely to be the use of antibodies from recovered COVID-19 patients. As of Saturday, there were almost 72,000 such patients worldwide. The virus has infected about 150,000, killing more than 5,500.

The use of survivor antibodies, serum therapy, dates back to 1891 when it was used successfully to treat a child with diphtheria. Since then, serum from recovered patients has been used "to stem outbreaks of viral diseases such as poliomyelitis, measles, mumps and influenza," according to a paper Friday in The Journal of Clinical Investigation.

"As we are in the midst of a worldwide pandemic, we recommend that institutions consider the emergency use (of serum from recovered patients) and begin preparations as soon as possible. Time is of the essence," wrote the paper's two authors, Arturo Casadevall of Johns Hopkins School of Public Health, and Liise-anne Pirofski of the Albert Einstein College of Medicine in New York.

All of the strategies, including the use of serum from recovered patients, have drawbacks. Transfusion of serum carries potential side effects, including fever, allergic reactions, and a very small risk of infectious disease transmission.

Collecting large amounts of serum from recovered patients could be a sizable task. It could turn out that serum from one recovered patient is only enough to save a single sick one, explained Kruse at Johns Hopkins. "It's a logistical challenge to put it together, but at the very least there are no hurdles (from the U.S. Food and Drug Administration) to producing the therapy."

Kruse advanced another technique in a paper published in late January in the journal F1000 Research.

His method seeks to take advantage of the new coronavirus' ability to latch onto and enter cells.

Scientists often talk about "cell receptors," which are essentially doors that allow a virus to enter the cell.

The "door" the new coronavirus is entering through is known as the ACE-2 protein. Kruse's technique involves detaching the external portion of ACE-2, which would act as a decoy for the virus. The virus would bind to the decoy, leaving it unable to reach the actual door into the cell, and thus, unable to cause infection.

"It won't realize, 'Oh gosh, this isn't a cell,'" Kruse explained in an interview. "The virus can't mutate away from this."

Kruse's decoy therapy would not be available until fall at the earliest. However, a similar version of the strategy is currently being tested in trials in China.

Using a drug for a new purpose

A faster option involves what's called "repurposing" a drug.

This is when a drug that has already been found safe and approved for treatment of one disease also is found useful in treating another. One example is the drug Sildenafil, which is sold as Viagra and used to treat both erectile dysfunction and pulmonary hypertension.

There are three ways in which scientists try to find an existing drug that can treat a new condition.

The rational method involves using drugs that have characteristics and targets that suggest they might be used to treat the new condition.

The computational method involves examining protein structures and using them to predict an existing drug that might work.

The final method takes advantage of the vast drug libraries possessed by companies and academic institutions. High-speed technology allows researchers to screen thousands of drugs very quickly to determine whether they will act against a specific target.

Considerable hope, interest and money have been invested in one drug not previously approved, remdesivir. The drug was previously tested against Ebola, but failed in trials.

Gilead Sciences, a Foster City, California-based biopharmaceutical company, announced that two clinical studies of the drug are beginning this month. Two more clinical trials of the drug are already underway in China.

In the U.S., the clinical trials process is slow and painstaking, taking several years and sometimes much longer.

'The idea is right'

Another approach to the new virus championed by numerous researchers is the use of lab-made proteins called monoclonal antibodies.

These confer what's called "passive immunity" and have been used previously to treat cancer, multiple sclerosis, cardiovascular disease and many other conditions.

"The use of monoclonal antibodies is a new era in infectious disease prevention which overcomes many drawbacks associated with serum therapy ... in terms of specificity, purity, low risk of blood-borne pathogen contamination and safety," wrote the authors of a recent paper in the Asian Pacific Journal of Allergy and Immunology.

The biotechnology company Regeneron, based in Tarrytown, New York, started work searching for a monoclonal antibody "for this particular virus in early/mid-January," said Christos Kyratsous, the company's vice president for infectious diseases and viral vector technologies. "But really we started working on it decades ago when we began building our unique end-to-end drug discovery and development technologies."

Gregory Poland, director of Mayo Clinic's Vaccine Research Group, said the use of monoclonal antibodies "needs to be designed and tested in this specific disease, but I wouldn't see any reason it wouldn't work. The idea is right."

Like other scientists, Poland was less hopeful that a vaccine would be developed anytime soon.

"We won't have a vaccine for this outbreak," he said. "It will be before the next (outbreak)."

Monoclonal antibodies do have pitfalls. They require extensive testing. Also, viruses can mutate and escape from the antibodies. Companies sometimes target two different parts of the virus to make it harder for the virus to mutate and elude the antibodies.

Ajay K. Sethi, associate professor of population health sciences at the University of Wisconsin-Madison, expressed support for the development of monoclonal antibodies.

"In my opinion, trying a strategy like monoclonal antibodies to provide passive immunity is a good idea," Sethi said. He added that given the technique's past successes, "it is hopeful, but not surprising."

Strategies for combating the new coronavirus will likely require reaching patients early before they get too sick. Toward that end, Kruse said he believes the U.S. should pursue the much broader coronavirus testing policy that South Korea adopted.

"Maybe in the next few weeks we will get to the point where we are testing everyone," he said.

12:26 pm EDT Mar. 15, 2020

What do you think @Hacky McAxe and @Lov_Dog and any other Science minded people on the Kennel?

I''m very skeptical of any news on a vaccine being "weeks away".

 

[Alexander the Great]

You have to be Croatian or Serbian or something in the blockhead region. ..that picture made me horny.
Good gear.

Corona and all the scavengers can go and fuck themselves

Sorted for atleast 8 months of homemade salt-cured, cold smoked delicious meats

 

[south of heaven]

@south of heaven if it's cross play does that mean I'm playing dudes with a keyboard and mouse on PC? Like I'm blaming them for all my deaths if it is lol

Yep I got my first kill after 3 rounds got to play it like fire storm nice and slow

 

[The DoggFather]

These motherfuckers need to be found.

1. Confiscate all the toilet paper, paper towels and tissues they have stockpiled

2. Flog the living daylights out of the *****.

3. Smash every toilet bowl in their house

4. Charge the *****

Happened in Murika. Some **** bought out all the sanitizer in his county looking to profit. Cops confiscated it and handed it out.

 

[Mr 95%]

Yeah I didn't know it existed and only came across it while looking up a bulldogs related article. Lurked for a little bit before joining up in 08.

I came for Ennis in 2013..actually that didn’t sound right..but anyway I stayed because of the excellent people on here

If only I had known about TK in 04, took me a most of my years as a supporter to come across this place. I don’t even know how I did lol, but very glad I found my second family life wouldn’t be the same without it. Definitely a privilege to be here.